Tenaya Therapeutics (TNYA) Free Cash Flow (2020 - 2026)
Tenaya Therapeutics (TNYA) posted quarterly Free Cash Flow of -$18.8 million for Q1 2026, up 18.76% year-over-year from -$15.8 million in Q1 2025, and down 34.65% quarter-over-quarter from -$13.9 million in Q4 2025.
Tenaya Therapeutics (TNYA) Free Cash Flow (2020 - 2026) Analysis & Trends
Tenaya Therapeutics' Free Cash Flow history runs 7 years deep, the most recent figure standing at -$18.8 million for Q1 2026.
- In Q1 2026, Free Cash Flow rose 18.76% year-over-year to -$18.8 million; the TTM figure through Mar 2026 stood at -$63.4 million (up 24.83% YoY), while the FY2025 annual figure was -$67.7 million, up 24.66% from the prior year.
- Free Cash Flow for Q1 2026 stood at -$18.8 million, down from -$13.9 million in the prior quarter.
- The five-year high for Free Cash Flow was -$3.7 million in Q4 2022, with the low at -$47.3 million in Q3 2022.
- The 5-year median for Free Cash Flow is -$23.1 million (2025), against an average of -$22.6 million.
- The sharpest annual moves came in 2022 and 2023: Free Cash Flow surged 78.16% in 2022, then slumped 492.03% in 2023.
- Tenaya Therapeutics' Free Cash Flow stood at -$3.7 million in 2022, then plunged by 492.03% to -$21.7 million in 2023, then rose by 22.0% to -$16.9 million in 2024, then grew by 17.56% to -$13.9 million in 2025, then sank by 34.65% to -$18.8 million in 2026.
- Business Quant data shows TNYA's Free Cash Flow at -$18.8 million in Q1 2026, -$13.9 million in Q4 2025, and -$14.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Tenaya Therapeutics | 151.50 Mn | 151.50 Mn | - | -3.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.59 Mn |
| Jun 30, 2026 | -3.59 Mn |
| Mar 31, 2026 | -18.77 Mn |
| Mar 31, 2026 | -18.77 Mn |
| Dec 31, 2025 | -13.94 Mn |
| Dec 31, 2025 | -13.94 Mn |
| Sep 30, 2025 | -14.50 Mn |
| Sep 30, 2025 | -14.50 Mn |
| Jun 30, 2025 | -16.14 Mn |
| Jun 30, 2025 | -16.14 Mn |
| Mar 31, 2025 | -23.11 Mn |
| Mar 31, 2025 | -23.11 Mn |
| Dec 31, 2024 | -16.91 Mn |
| Dec 31, 2024 | -16.91 Mn |
| Sep 30, 2024 | -20.02 Mn |
| Sep 30, 2024 | -20.02 Mn |
| Jun 30, 2024 | -24.25 Mn |
| Jun 30, 2024 | -24.25 Mn |
| Mar 31, 2024 | -28.67 Mn |
| Mar 31, 2024 | -28.67 Mn |